Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
80M
-
Number of holders
-
92
-
Total 13F shares, excl. options
-
30.8M
-
Shares change
-
+1.82M
-
Total reported value, excl. options
-
$813M
-
Value change
-
+$45.3M
-
Number of buys
-
44
-
Number of sells
-
-37
-
Price
-
$25.80
Significant Holders of Akero Therapeutics, Inc. - Common Stock, par value $0.0001 per share (AKRO) as of Q4 2020
110 filings reported holding AKRO - Akero Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2020.
Akero Therapeutics, Inc. - Common Stock, par value $0.0001 per share (AKRO) has 92 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30.8M shares
of 80M outstanding shares and own 38.52% of the company stock.
Largest 10 shareholders include ATP Life Science Ventures, L.P. (5.83M shares), JANUS HENDERSON GROUP PLC (3.49M shares), venBio Partners LLC (2.44M shares), Redmile Group, LLC (2.32M shares), ALKEON CAPITAL MANAGEMENT LLC (2.29M shares), WELLINGTON MANAGEMENT GROUP LLP (1.67M shares), HILLHOUSE CAPITAL ADVISORS, LTD. (1.66M shares), BlackRock Inc. (1.35M shares), VANGUARD GROUP INC (884K shares), and BOXER CAPITAL, LLC (831K shares).
This table shows the top 92 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.